Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Deferred Tax Liability (2023 - 2025)

Coherus Oncology's Non-Current Deferred Tax Liability history spans 2 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, changed N/A, while the annual FY2025 figure was $1.1 million, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $1.1 million at Coherus Oncology, roughly flat from $1.1 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $1.1 million in Q4 2023 and bottomed at $1.1 million in Q4 2023.